Q1 2022 Results
Company overview
Financial performance
CRM
Financial review
Immunology
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
remibrutinib - BTK inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04109313 (CLOU064A2201E1)
Chronic spontaneous urticaria (CSU)
Phase 2
250
Long-term safety and tolerability
Selected dose of LOU064 taken orally twice a day (morning and evening) from day
1 to week 52
Patients with CSU who have participated in preceding studies with LOU064
Target Patients
Read-out Milestone(s)
H2 2022
Publication
Primary: 2023
References
Abbreviations
Hematology
Biosimilars
Global Health
66 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation